← Leaderboards
Besim Ogretmen
Medical University Of South Carolina
$19,638,711
Attributed
$19,638,711
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,934,463 · 15
By mechanism
R01$15,883,774 · 5
P01$11,383,118 · 4
P30$6,297,785 · 5
R56$369,786 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Sphingolipids”
- Yusuf Awni Hannun · Medical University Of South Carolina$30,274,744
- Timothy Tun Hla · Boston Children'S Hospital$22,231,469
- Sarah Spiegel · Virginia Commonwealth University$19,116,930
- Julie D Saba · University Of California, San Francisco$15,245,252
- Charles E Chalfant · Va Veterans Administration Hospital$12,100,824
- Lina M Obeid · Medical University Of South Carolina$11,320,750
Research focus
SphingolipidsSignal TransductionBaseCeramidesMediatingCancer CellMalignant NeoplasmsRegulationMolecularDesignTumorResponseCell DeathMetabolismLipidsComplexDihydroceramide DesaturaseIn VivoCellsGrowthPathogenesisBiologicalProteinsPositioning Attribute
Grant awards (101)
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$397,660
R01 · FY2025 · DE · contact PI
Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer$371,477
R01 · FY2025 · CA · contact PI
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC$371,074
R01 · FY2025 · CA · contact PI
Lipidomics Shared Resource$80,365
P30 · FY2025 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$389,707
R01 · FY2024 · DE · contact PI
Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer$384,227
R01 · FY2024 · CA · contact PI
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC$352,520
R01 · FY2024 · CA · contact PI
Lipidomics Shared Resource$75,823
P30 · FY2024 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$397,660
R01 · FY2023 · DE · contact PI
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC$371,074
R01 · FY2023 · CA · contact PI
Lipidomics Shared Resource$61,757
P30 · FY2023 · CA · contact PI
Developmental Cancer Therapeutics$50,637
P30 · FY2023 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$393,357
R01 · FY2022 · DE · contact PI
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis$335,142
R01 · FY2022 · CA · contact PI
Lipidomics Shared Resource$61,757
P30 · FY2022 · CA · contact PI
Developmental Cancer Therapeutics$50,637
P30 · FY2022 · CA · contact PI
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling$1,683,403
P01 · FY2021 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$396,078
R01 · FY2021 · DE · contact PI
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis$341,981
R01 · FY2021 · CA · contact PI
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling$279,178
P01 · FY2021 · CA · contact PI
Core D: Administration$114,395
P01 · FY2021 · CA · contact PI
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis$63,039
R01 · FY2021 · CA · contact PI
Lipidomics Shared Resource$61,757
P30 · FY2021 · CA · contact PI
Developmental Cancer Therapeutics$50,637
P30 · FY2021 · CA · contact PI
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling$1,747,709
P01 · FY2020 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$373,750
R01 · FY2020 · DE · contact PI
Sphingolipid Metabolism and Signaling in the Regulation of Senescence and Aging$369,786
R56 · FY2020 · AG · contact PI
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis$341,981
R01 · FY2020 · CA · contact PI
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling$274,051
P01 · FY2020 · CA · contact PI
Core D: Administration$110,963
P01 · FY2020 · CA · contact PI
Research Supplement to Promote Diversity in Health-Related Research$63,039
R01 · FY2020 · CA · contact PI
Lipidomics Shared Resource$61,757
P30 · FY2020 · CA · contact PI
Developmental Cancer Therapeutics$50,637
P30 · FY2020 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$551,905
R01 · FY2019 · DE · contact PI
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis$331,721
R01 · FY2019 · CA · contact PI
Lipidomics Shared Resource$59,735
P30 · FY2019 · CA · contact PI
Developmental Cancer Therapeutics$48,980
P30 · FY2019 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$16,195
R01 · FY2019 · DE · contact PI
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling$1
P01 · FY2019 · CA · contact PI
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling$1,836,914
P01 · FY2018 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$373,750
R01 · FY2018 · DE · contact PI
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis$341,981
R01 · FY2018 · CA · contact PI
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling$283,520
P01 · FY2018 · CA · contact PI
Core D: Administration$114,397
P01 · FY2018 · CA · contact PI
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling$1,780,770
P01 · FY2017 · CA · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$373,750
R01 · FY2017 · DE · contact PI
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression$310,213
R01 · FY2017 · CA · contact PI
Regulation of Telomerase by Sphingolipid Signaling in Lung Cancer$205,835
R01 · FY2017 · CA · contact PI
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling$128,253
P01 · FY2017 · CA · contact PI
Core D: Administration$51,477
P01 · FY2017 · CA · contact PI
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling$1,811,148
P01 · FY2016 · CA · contact PI
COBRE in Lipidomics and Pathobiology$1,094,825
P30 · FY2016 · GM · contact PI
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy$373,750
R01 · FY2016 · DE · contact PI
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression$310,213
R01 · FY2016 · CA · contact PI
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling$299,900
P01 · FY2016 · CA · contact PI
Regulation of Telomerase by Sphingolipid Signaling in Lung Cancer$205,835
R01 · FY2016 · CA · contact PI
Core D: Administration$114,397
P01 · FY2016 · CA · contact PI
COBRE in Lipidomics and Pathobiology$1,094,825
P30 · FY2015 · GM · contact PI
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression$310,213
R01 · FY2015 · CA · contact PI
Regulation of Telomerase by Sphingolipid Signaling in Lung Cancer$205,835
R01 · FY2015 · CA · contact PI
RESEARCH PILOT PROJECTS PROGRAM$147,499
P30 · FY2015 · GM · contact PI
COBRE in Lipidomics and Pathobiology$1,094,825
P30 · FY2014 · GM · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$346,809
R01 · FY2014 · DE · contact PI
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression$300,906
R01 · FY2014 · CA · contact PI
Regulation of Telomerase by Sphingolipid Signaling in Lung Cancer$199,660
R01 · FY2014 · CA · contact PI
COBRE in Lipidomics and Pathobiology$1,056,507
P30 · FY2013 · GM · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$332,937
R01 · FY2013 · DE · contact PI
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression$310,213
R01 · FY2013 · CA · contact PI
Regulation of Telomerase by Sphingolipid Signaling in Lung Cancer$205,662
R01 · FY2013 · CA · contact PI
COBRE in Lipidomics and Pathobiology$1,094,825
P30 · FY2012 · GM · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$386,537
R01 · FY2012 · DE · contact PI
Regulation of ER Stress by de novo Ceramide Synthesis in Head and Neck Cancers$162,715
P01 · FY2012 · CA · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$339,803
R01 · FY2011 · DE · contact PI
Regulation of Telomerase by Ceramide in Lung Cancer$201,015
R01 · FY2011 · CA · contact PI
Regulation of ER Stress by de novo Ceramide Synthesis in Head and Neck Cancers$156,333
P01 · FY2011 · CA · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$39,728
R01 · FY2011 · DE · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$350,313
R01 · FY2010 · DE · contact PI
Regulation of Telomerase by Ceramide in Lung Cancer$207,232
R01 · FY2010 · CA · contact PI
Regulation of ER Stress by de novo Ceramide Synthesis in Head and Neck Cancers$166,604
P01 · FY2010 · CA · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$265,609
R01 · FY2009 · DE · contact PI
Regulation of Telomerase by Ceramide in Lung Cancer$207,232
R01 · FY2009 · CA · contact PI
Regulation of ER Stress by de novo Ceramide Synthesis in Head and Neck Cancers$162,989
P01 · FY2009 · CA · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$265,609
R01 · FY2008 · DE · contact PI
Regulation of Telomerase by Ceramide in Lung Cancer$207,232
R01 · FY2008 · CA · contact PI
Regulation of ER Stress by de novo Ceramide Synthesis in Head and Neck Cancers$104,001
P01 · FY2008 · CA · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$76,650
R01 · FY2008 · DE · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$268,563
R01 · FY2007 · DE · contact PI
Regulation of Telomerase by Ceramide in Lung Cancer$207,232
R01 · FY2007 · CA · contact PI
C18-Ceramide in Head & Neck Cancer Growth and Therapy$276,584
R01 · FY2006 · DE · contact PI
Regulation of Telomerase by Ceramide in Lung Cancer$198,986
R01 · FY2006 · CA · contact PI
Regulation of Telomerase by Ceramide in Lung Cancer$46,895
R01 · FY2006 · CA · contact PI
C18-Ceramide in Head &Neck Cancer Growth and Therapy$307,490
R01 · FY2005 · DE
Regulation of Telomerase by Ceramide in Lung Cancer$203,775
R01 · FY2005 · CA
C18-Ceramide in Head &Neck Cancer Growth and Therapy$57,724
R01 · FY2005 · DE
Regulation of Telomerase by Ceramide in Lung Cancer$46,895
R01 · FY2005 · CA
Regulation of Telomerase by Ceramide in Lung Cancer$203,775
R01 · FY2004 · CA
Regulation of Telomerase by Ceramide in Lung Cancer$46,895
R01 · FY2004 · CA
Regulation of Telomerase by Ceramide in Lung Cancer$203,775
R01 · FY2003 · CA
Regulation of Telomerase by Ceramide in Lung Cancer$46,895
R01 · FY2003 · CA
Regulation of Telomerase by Ceramide in Lung Cancer$226,708
R01 · FY2002 · CA
Regulation of Telomerase by Ceramide in Lung Cancer$43,473
R01 · FY2002 · CA